The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Technologies

Economic forces are forging a new payer environment with value demonstration at its core, and the threshold for evidence on new biopharmaceuticals and medical technologies is higher than ever. In response, pharma, biotech, and med device companies are developing new, increasingly more complex go-to-market strategies that include taking greater ownership of the patient pathway, developing beyond the pill solutions, proposing novel pricing schemes, and integrating, value-based market access approaches.

Download our briefing for insights on these developing trends and important considerations for manufacturers who are considering value-based contracts with payers.

Download the PMA Briefing